ELP5

Across TCGA pan-cancer cohorts, ELP5 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELP5 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELP5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ELP5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where ELP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.496	0.295	.011	29	view →
UCEC	DFS	Median	II,III,IV	0.505	0.870	.030	16	view →
LUAD	OS	Quartile	II,III,IV	0.201	0.712	.008	12	view →
HNSC	OS	Tertile	III,IV	0.836	0.520	.009	10	view →
CCRCC	DFS	Median	II,III,IV	0.962	0.847	.046	2	view →
LSCC	DFS	Median	All	0.892	0.979	.006	2	view →
GBM	DFS	Median	All	0.252	0.464	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELP5–PDAC (DFS)

Open the PDAC breakdown →